Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Business Times.
Press releases published on March 20, 2025
NevGold Increases the Size of the Zeus Copper Project by Approximately 50% Or 1,000 Hectares in the Hercules Copper District, Idaho
GlobeNewswire
·
March 20, 2025
Vancouver, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) -- NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that it has staked an additional 147 claims, approximately 1,000 hectares or 10 …
Academy Sports + Outdoors Reports Fourth Quarter and Fiscal 2024 Results
GlobeNewswire
·
March 20, 2025
Fourth Quarter Comparable Sales Declined (3.0)%: a +190 Basis Point Improvement vs. Third Quarter 2024 Fourth Quarter Diluted GAAP EPS of $1.89: Above the Midpoint of Updated Guidance Provided Company Announces Launch of Jordan Brand in 145 Stores and …
AI-powered Chemical Manufacturing Market to Expand at 28.8% CAGR, Generating US$ 37.6 Billion by 2034 as Industry Embraces Smart Technologies | Latest Report by Transparency Market Research
GlobeNewswire
·
March 20, 2025
Wilmington, Delaware, Transparency Market Research, Inc. –, March 20, 2025 (GLOBE NEWSWIRE) -- The future of the chemical industry is being reshaped by artificial intelligence, driving unprecedented efficiency and innovation. The AI-based Chemical …
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
GlobeNewswire
·
March 20, 2025
PHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that the U.S. Food and Drug Administration …
Antitrust and Industrial Organization Expert Matthew Backus Affiliates with Compass Lexecon
GlobeNewswire
·
March 20, 2025
WASHINGTON, March 20, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced that Dr. Matthew Backus has affiliated with the firm’s Compass Lexecon subsidiary. Dr. Backus is an expert in antitrust, microeconomics and industrial …
Intravenous Equipment Market is Projected US$ 35,2670 Million, Expanding at 5.9% CAGR by 2035 | Fact.MR Analysis
GlobeNewswire
·
March 20, 2025
Rockville, MD, March 20, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global intravenous (IV) equipment market is estimated to reach a valuation of US$ 19,881 million in 2025 and is expected to …
Revival Gold Enters Marketing Services Agreement
GlobeNewswire
·
March 20, 2025
TORONTO, March 20, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) ("Revival Gold" or the "Company") is pleased to announce that the Company has entered into a marketing service agreement (the “Agreement”) with Resource Stock Digest (“ …
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
GlobeNewswire
·
March 20, 2025
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025 Launch preparations on track toward goal to treat first patient in 3Q 2025 CLEVELAND, March 20, …
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
GlobeNewswire
·
March 20, 2025
Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to …
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
GlobeNewswire
·
March 20, 2025
Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseases Highly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third …
Emerging Markets Report: Ceilings & Floors
GlobeNewswire
·
March 20, 2025
An Emerging Markets Sponsored Commentary ORLANDO, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- At the Emerging Market Report we are definitively newshounds, constantly looking to see what news from a Company could further its fortunes or more rarely, what news …
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 20, 2025
Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer’s Disease Subgroup 2025 Objective: Advance …
FPO/TPO Synthetic Roofing Membrane Market is Projected USD 1,489.0 Million, Expanding at 4.4% CAGR by 2035 | Fact.MR Analysis
GlobeNewswire
·
March 20, 2025
Rockville, MD, March 20, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the FPO/TPO synthetic roofing membrane market was valued at USD 928.3 million in 2024 and is expected to grow at a CAGR of 4.4% …
Avalo Reports 2024 Financial Results and Recent Business Updates
GlobeNewswire
·
March 20, 2025
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide …
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 20, 2025
Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025 On track to …
Paramount Secures Approval from Oregon State Agencies for Proposed Technologies and Processes at Its Wholly Owned Grassy Mountain Gold Project
GlobeNewswire
·
March 20, 2025
WINNEMUCCA, Nevada, March 20, 2025 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) announced today that, at a public meeting of the Technical Review Team (“TRT”), the state agencies voted unanimously to …
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
GlobeNewswire
·
March 20, 2025
AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024 Obe-cel MHRA and EMA marketing authorizations expected in H2 2025 …
Destination XL Group, Inc. Reports Fiscal 2024 Fourth Quarter and Full-Year Financial Results
GlobeNewswire
·
March 20, 2025
CANTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (NASDAQ: DXLG), the largest integrated commerce specialty retailer of Big + Tall men’s clothing and shoes, today reported financial results for the fourth quarter and fiscal year …
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire
·
March 20, 2025
$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), …
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
GlobeNewswire
·
March 20, 2025
Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and …